Daratumumab SC: daratumumab + rHuPH20 clinical trials

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

This study is looking at a new treatment called daratumumab for people with 'high-risk smoldering multiple myeloma' (SMM). It compares this treatment to simply monitoring the condition, to see if daratumumab can delay the disease getting worse.